TABLE 1

Baseline characteristics of the study population (hypersensitivity pneumonitis patients receiving antifibrotics)

Patients30
Age years70.2±8.4
Sex
 Male26 (86.7)
 Female4 (13.3)
Smoking status
 Ex-smokers19 (63.3)
 Never-smokers11 (36.7)
Antifibrotics
 Pirfenidone14 (46.7)
 Nintedanib16 (53.3)
Identification of inciting antigen25# (83.3)
Surgical lung biopsy7 (23.3)
Comorbidities
 GORD12 (40)
 Pulmonary hypertension9 (30)
 Arterial hypertension13 (43.3)
 Diabetes6 (20)
 Coronary artery disease6 (20)
Supplementary oxygen11 (36.7)
FVC % pred74.2 ±18.3
DLCO % pred46.9±16

Data are presented as n, mean±sd or n (%). GORD: gastro-oesophageal reflux disease; FVC: forced vital capacity; DLCO: diffusing capacity of the lung for carbon monoxide. #: avian n=21, house mould n=3, isocyanate n=1.